ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年12月18日 09時00分
Source:
Eisai
エーザイ、川島工園に第5製剤棟が竣工 抗がん剤「レンビマ(R)」製剤の自社生産機能を強化
東京, 2020年12月18日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、岐阜県の川島工園内で建設中であった第 5 製剤棟が竣工したことをお知らせします。
第5製剤棟は、抗がん剤製剤の専用施設(総床面積約 4,500m2)です。本施設では、高活性物質である抗がん剤を取り扱うことから、薬物の交差汚染防止をはじめ、作業者への暴露防止など、高活性物質の様々な「封じ込め」対策を行い、より安全に製造が可能となるデザインになっています。本施設においては、全世界で需要が拡大している自社創製の抗がん剤「レンビマ(R)」の製造を 2021 年度より行う予定です。また、将来的に他の抗がん剤の製造設備の導入が可能なスペースも有しています。なお、第 5製剤棟建設に伴う総投資額は約 50 億円です。
川島工園は、1966 年に開所した当社のグローバルな製造(製剤)拠点であり、また、デジタル技術や新技術の活用などの新たな取り組みを行う、当社のグローバル生産活動におけるロールモデル工場の役割も担っています。今回の第 5 製剤棟の竣工を機に、国内での高品質な医薬品の安定供給体制をより拡充させるとともに、日本および世界の患者様とそのご家族のベネフィット向上により一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202085.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
Fujitsu collaborates with global suppliers in decarbonization initiative to exchange product-level primary data on CO2 emissions
Nov 15, 2024 10:13 JST
TANAKA Successfully Develops the World's First[1] Manufacturing Technology for Platinum Materials with Nano-Sized Crystal Grains
Nov 15, 2024 04:00 JST
myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth
Nov 14, 2024 20:00 JST
ULVAC Launches Oil Rotary Vacuum Pump Gv135
Nov 14, 2024 10:00 JST
MHI Publishes MHI REPORT 2024
Nov 13, 2024 16:52 JST
SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization
Nov 13, 2024 12:38 JST
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 12:05 JST
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 13, 2024 11:16 JST
All-New Triton Wins Special Award at the RJC Car of the Year for 2025
Nov 12, 2024 22:09 JST
Toyota: HySE to participate in the Dakar 2025 "Mission 1000 ACT2" with the HySE-X2, to tackle further technical challenges
Nov 12, 2024 20:04 JST
NEC participates in COP29 climate change conference
Nov 12, 2024 19:25 JST
JA Mitsui Leasing and Fujitsu collaborate on simulation-driven field trials to optimize commercial EV adoption and drive decarbonization
Nov 12, 2024 13:57 JST
Macnica publishes Integrated Report on the theme of 'An Introductory Guide to Macnica's Mechanism'
Nov 12, 2024 13:00 JST
Hitachi: Established the Open Source Program Office (OSPO) to Globally Lead the Strategic Utilization of OSS
Nov 11, 2024 10:31 JST
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
Nov 08, 2024 10:31 JST
Hitachi High-Tech and University of Tokyo Promote Joint Research for the Practical Application of High-resolution Laser-PEEM in the Semiconductor Field
Nov 07, 2024 18:19 JST
More Latest Release >>
Related Release
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
10/31/2024 1:56:00 PM JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/31/2024 11:33:00 AM JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
10/17/2024 8:01:00 PM JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
10/17/2024 3:59:00 PM JST
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
10/16/2024 7:14:00 PM JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
10/8/2024 2:00:00 PM JST
More Press release >>